Copyright
©2014 Baishideng Publishing Group Co.
World J Clin Oncol. May 10, 2014; 5(2): 125-133
Published online May 10, 2014. doi: 10.5306/wjco.v5.i2.125
Published online May 10, 2014. doi: 10.5306/wjco.v5.i2.125
Table 3 Response to neoadjuvant platinum based chemotherapy trials in triple-negative breast cancer
Ref. | Yr | No. | Regimen | PCR |
Garber et al[20] | 2006 | 28 | Cisplatin | 21% |
Silver et al[21] | 2010 | 28 | Cisplatin 3 wk × 4 | 22% |
Byrski et al[22] | 12 | Cisplatin | 83% | |
2Byrski et al[23] | 2009 | 25 | Cisplatin + paclitaxel + GSF | 72% |
Ryan et al[24] | 2009 | 51 | Cisplatin + bevacizumab 3 wk × 4 | 72% |
Frasci et al[25] | 2009 | 74 | Cisplatin + epirubicin + paclitaxel wk × 8 | 65% |
Sirohi et al[26] | 2008 | 62 | Platinum1 + epirubicin + 5-FU (infusion) | 88% (cCR) |
Sikov et al[27] | 2007 | 10 | Carboplatin 3 wk × 4 + paclitaxel wk × 16 | 50% |
Leone et al[28] | 2009 | 125 | Platinum1 + docetaxel 3 wk × 4 | 29% |
Platinum + docetaxel → AC 3 wk × 4 | 40% |
- Citation: Yadav BS, Sharma SC, Chanana P, Jhamb S. Systemic treatment strategies for triple-negative breast cancer. World J Clin Oncol 2014; 5(2): 125-133
- URL: https://www.wjgnet.com/2218-4333/full/v5/i2/125.htm
- DOI: https://dx.doi.org/10.5306/wjco.v5.i2.125